Healthy Clinical Trial
Official title:
An Intervention Study to Explore Potential Metabolic Effects of Ruminococcus Torques Strain ATCC 27756 in Healthy Adults
Verified date | September 2023 |
Source | University Hospital, Gentofte, Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomized, placebo controlled crossover study investigating the potential metabolic effects of the naturally occurring gut microbe Ruminococcus torques in healthy, overweight adults.
Status | Completed |
Enrollment | 32 |
Est. completion date | September 14, 2023 |
Est. primary completion date | September 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 40 years - Self-reported good health - Caucasian - Body Mass Index > 27 kg/m^2 Exclusion Criteria: - Any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease. - Use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial - Use of antibiotics during the recent three months - Acute or chronic gastrointestinal symptoms - Lactose intolerance - Pregnancy - ongoing or planned - Smoking - Alcohol or drug abuse - Use of creatine as dietary supplement during study period - Plasma creatinine above the normal range (>105 µmol/L for men and >90 µmol/L for women) - Known significant liver disease or plasma alanine transaminase concentration = 3 × normal value - Values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges |
Country | Name | City | State |
---|---|---|---|
Denmark | Gentofte Hospital | Hellerup |
Lead Sponsor | Collaborator |
---|---|
Oluf Pedersen | Technical University of Denmark, University Hospital, Gentofte, Copenhagen, University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Heart rate | Changes in heart rate during study day | During the six hours of the study day (up to six weeks between study days) | |
Other | Blood pressure | Changes in blood pressure during study day | During the six hours of the study day (up to six weeks between study days) | |
Other | Various hormones related to metabolism | Differences in measures of various hormones during the study day | During the six hours of the study day (up to six weeks between study days) | |
Other | Standard hematologic blood samples | Differences in measures of standard hematologic biomarkers in the blood, such as platelets | During the six hours of the study day (up to six weeks between study days) as well as one week after each study day | |
Other | Standard clinical biochemical variables | Differences in measurements of standard clinical biochemical biomarkers, such as alanine transaminase and creatinine | During the six hours of the study day (up to six weeks between study days) as well as one week after each study day | |
Primary | Matsuda Insulin Sensitivity Index | Differences in calculated Matsuda Insulin Sensitivity Index between the two study days | During two hours following a standard glucose solution (75g glucose in 250 ml of water) after the second dose of Ruminococcus or placebo has been given during the study day (second measurement up to six weeks later) | |
Secondary | Ruminococcus Irisin-Like Peptide (RUCILP) | Differences in plasma RUCILP concentration between the two study days | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Peptide YY | Differences in plasma Peptide YY concentration between the two study days | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Glucose profile | Difference in blood glucose profile during the entirety of the study day | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Resting energy expenditure | Difference in resting energy expenditure measured by indirect calorimetric | Three times during the study day for 15 minutes | |
Secondary | Activation of brown adipose tissue | Difference in temperature measured with thermographic camera of the collar bones | 15 minutes 3 times during each study day | |
Secondary | Bone dynamics | Differences in measures of biomarkers of bone turnover in blood | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Gut microbiota | Changes in gut microbiota composition after each intervention | Samples taken prior to each visit (experimental days and follow-up visits) | |
Secondary | Metabolome | Changes is plasma metabolome after intervention | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Area Under the Plasma Concentration Versus Time Curve of Gucagon-Like Peptide-1 | Differences in area under the curve between the two study days | During the six hours of the study day (up to six weeks between study days) | |
Secondary | Cytokine profile | Differences in the cytokine profiles during the study day | During the six hours of the study day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |